A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

BACKGROUND: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACR) are the standard treatments for esophageal squamous cell carcinoma (ESCC). However, the 5-year overall survival (OS) rate is still far from satisfactory. In recent years, immune checkpoint inhibitors (ICIs) have show...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: Zheng, Yan, Liu, Xian-Ben, Sun, Hai-Bo, Xu, Jinliang, Shen, Sining, Ba, Yu-Feng, Yan, Ming, Qin, Zimin, Liu, Bao-Xing, Wang, Zong-Fei, Liu, Shi-Lei, Zhang, Rui-Xiang, Chen, Pei-Nan, Liang, Guang-Hui, Yuan, Dongfeng, Li, Zhen-Xuan, Liu, Qi, Wang, Hao-Ran, Li, Hao-Miao, Lv, Hongwei, Ma, Xiaochao, Zhu, Jianping, Yu, Yong-Kui, Xing, Wen-Qun
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7859818/
https://ncbi.nlm.nih.gov/pubmed/33553366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-5404
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados